Atai Life Sciences Stock Price, News & Analysis (NASDAQ:ATAI)

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATAI shares.
View ATAI analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price targets for Atai Life Sciences' shares. Their ATAI share price targets range from $9.00 to $20.00. On average, they anticipate the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 1,042.9% from the stock's current price.
View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts.

Atai Life Sciences' stock was trading at $2.66 on January 1st, 2023. Since then, ATAI shares have decreased by 57.9% and is now trading at $1.12.
View the best growth stocks for 2023 here.

Atai Life Sciences saw a decrease in short interest in November. As of November 15th, there was short interest totaling 5,090,000 shares, a decrease of 9.6% from the October 31st total of 5,630,000 shares. Based on an average daily trading volume, of 526,800 shares, the short-interest ratio is presently 9.7 days. Currently, 4.5% of the shares of the company are short sold.
View Atai Life Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our ATAI earnings forecast.

Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.17 million for the quarter. Atai Life Sciences had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 20,043.11%.

ETFs with the largest weight of Atai Life Sciences (NASDAQ:ATAI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).

(ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Atai Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.38%), AdvisorShares Investments LLC (0.11%), Legal & General Group Plc (0.04%), American Century Companies Inc. (0.03%), HighTower Advisors LLC (0.03%) and Qube Research & Technologies Ltd (0.02%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao.
View institutional ownership trends.

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.